TD Cowen analyst Ryan Langston lowered the firm’s price target on Tenet Healthcare (THC) to $230 from $233 and keeps a Buy rating on the shares. The firm updated its model as they now see a slim chance of an ACA subsidy extension and are now contemplating associated payor mix headwinds.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target lowered to $229 from $252 at Wells Fargo
- Tenet Healthcare price target raised to $247 from $232 at Morgan Stanley
- Hospital stocks lower after Republicans propose Medicare funding cut
- Tenet Healthcare price target raised to $257 from $238 at Guggenheim
- Tenet Healthcare Board Member Resigns, Board Size Reduced